Andrew Rakeman, Ph.D.
Director of Discovery Research for JDRF
Andrew Rakeman, Ph.D., is the director of discovery research for JDRF, where he develops key industry partnerships and executes the strategic framework for the Beta Cell Regeneration and Immune Therapies Programs. He is primarily responsible for addressing scientific gaps in the drug discovery and development pipeline in order to bring the most promising and innovative therapeutics to market as quickly as possible. He also manages a portfolio of academic research grants for JDRF, and leads strategic partnerships with biotechnology and pharmaceutical companies, including Johnson & Johnson, Eli Lilly and Company, and the Genomics Institute of the Novartis Research Foundation.
Dr. Rakeman holds an undergraduate degree in biology from Boston University and a doctorate from Weill Cornell Medical College. His graduate training was conducted in the laboratory of Dr. Kathryn Anderson at the Sloan-Kettering Institute, studying the genetic and cellular regulation of axis formation and patterning in the mouse embryo. He has authored and coauthored several papers in the areas of developmental biology and cell biology. Dr. Rakeman is frequently invited as a speaker to meetings and symposia for both scientific and lay audiences.